150 related articles for article (PubMed ID: 28649983)
41. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Leonard JP; Kolibaba KS; Reeves JA; Tulpule A; Flinn IW; Kolevska T; Robles R; Flowers CR; Collins R; DiBella NJ; Papish SW; Venugopal P; Horodner A; Tabatabai A; Hajdenberg J; Park J; Neuwirth R; Mulligan G; Suryanarayan K; Esseltine DL; de Vos S
J Clin Oncol; 2017 Nov; 35(31):3538-3546. PubMed ID: 28862883
[TBL] [Abstract][Full Text] [Related]
42. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
[TBL] [Abstract][Full Text] [Related]
43. Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
Palmowski M; Zechmann C; Satzl S; Bartling S; Hallscheidt P
Ann Hematol; 2008 Apr; 87(4):337-8. PubMed ID: 17929016
[No Abstract] [Full Text] [Related]
44. Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.
Kang HJ; Kim WS; Suh C; Park YH; Kim BS; Yuh YJ; Ryoo BY
Cancer Chemother Pharmacol; 2008 Jul; 62(2):299-304. PubMed ID: 17922274
[TBL] [Abstract][Full Text] [Related]
45. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Ketterer N; Coiffier B; Thieblemont C; Fermé C; Brière J; Casasnovas O; Bologna S; Christian B; Connerotte T; Récher C; Bordessoule D; Fruchart C; Delarue R; Bonnet C; Morschhauser F; Anglaret B; Soussain C; Fabiani B; Tilly H; Haioun C
Ann Oncol; 2013 Apr; 24(4):1032-7. PubMed ID: 23235801
[TBL] [Abstract][Full Text] [Related]
46. Promising new combination therapy for non-GCB DLBCL.
Gourd E
Lancet Oncol; 2019 May; 20(5):e245. PubMed ID: 30930026
[No Abstract] [Full Text] [Related]
47. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
[TBL] [Abstract][Full Text] [Related]
48. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Kühnl A; Cunningham D; Counsell N; Hawkes EA; Qian W; Smith P; Chadwick N; Lawrie A; Mouncey P; Jack A; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Rosenwald A; Ott G; Horn H; Ziepert M; Pfreundschuh M; Linch D
Ann Oncol; 2017 Jul; 28(7):1540-1546. PubMed ID: 28398499
[TBL] [Abstract][Full Text] [Related]
49. Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09).
Yoon DH; Sohn BS; Oh SY; Lee WS; Lee SM; Yang DH; Huh J; Suh C
Oncotarget; 2017 Feb; 8(8):13367-13374. PubMed ID: 28076329
[TBL] [Abstract][Full Text] [Related]
50. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.
Meguro A; Ozaki K; Sato K; Oh I; Fujiwara S; Hosonuma R; Sasazaki M; Kikuchi Y; Hirata Y; Yamamoto C; Uesawa M; Kobayashi H; Matsu H; Okabe H; Uehara E; Nishikawa A; Tatara R; Hatano K; Yamamoto C; Matsuyama T; Toshima M; Ueda M; Ohmine K; Suzuki T; Mori M; Nagai T; Muroi K; Ozawa K
Leuk Lymphoma; 2012 Jan; 53(1):43-9. PubMed ID: 21864040
[TBL] [Abstract][Full Text] [Related]
51. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
52. Genetic polymorphism at
Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
[No Abstract] [Full Text] [Related]
53. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
[TBL] [Abstract][Full Text] [Related]
54. Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma.
Yoo KH; Lee JY; Lim SH; Ko YH; Kim SJ; Kim WS
Acta Haematol; 2015; 133(2):179-82. PubMed ID: 25323539
[TBL] [Abstract][Full Text] [Related]
55. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
56. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
Offner F; Samoilova O; Osmanov E; Eom HS; Topp MS; Raposo J; Pavlov V; Ricci D; Chaturvedi S; Zhu E; van de Velde H; Enny C; Rizo A; Ferhanoglu B
Blood; 2015 Oct; 126(16):1893-901. PubMed ID: 26232170
[TBL] [Abstract][Full Text] [Related]
57. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Fisher RI
Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
[No Abstract] [Full Text] [Related]
58. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
Iioka F; Izumi K; Kamoda Y; Akasaka T; Ohno H
Int J Clin Oncol; 2016 Jun; 21(3):498-505. PubMed ID: 26463529
[TBL] [Abstract][Full Text] [Related]
59. Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma.
García-Suárez J; Flores E; Callejas M; Arribas I; Gil-Fernández JJ; Olmedilla G; Curto N; Guillén H; Casco CR; Martín Y; Burgaleta C
Br J Haematol; 2013 Feb; 160(4):510-4. PubMed ID: 23228045
[TBL] [Abstract][Full Text] [Related]
60. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.
Lamy T; Damaj G; Soubeyran P; Gyan E; Cartron G; Bouabdallah K; Gressin R; Cornillon J; Banos A; Le Du K; Benchalal M; Moles MP; Le Gouill S; Fleury J; Godmer P; Maisonneuve H; Deconinck E; Houot R; Laribi K; Marolleau JP; Tournilhac O; Branger B; Devillers A; Vuillez JP; Fest T; Colombat P; Costes V; Szablewski V; Béné MC; Delwail V;
Blood; 2018 Jan; 131(2):174-181. PubMed ID: 29061568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
